Stem Cells

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

Data Integrity

Data Integrity: Drivers, Challenges, and Key Program Elements

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Adaptive Trials

Designing for Change: Adaptive Clinical Trials and the Evolving Path to Regulatory Acceptance

Pharma's Almanac

Personalized

Regulatory Innovation for a More Personalized Era of Medicine

Pharma's Almanac

Expedited Pathways

Accelerated Pathways: Are They Delivering on Their Promise?

David Alvaro, Ph.D.

Pharma's Almanac

Clinical Evidence

Rethinking Clinical Evidence Requirements in Rare Diseases

David Alvaro, Ph.D.

Pharma's Almanac

Supply Chain

Outsourcing, Fragmentation, and the New Supply Chain Resilience Challenge

Pharma's Almanac

Outsourcing

The Hidden Operational Costs of Multi-Vendor Outsourcing Models

Pharma's Almanac

AI in Manufacturing

Validating and Governing AI in GMP Manufacturing

Pharma's Almanac

AI Data Integrity

Data Integrity in the Age of AI-Assisted Manufacturing

Pharma's Almanac

PAT

Real-Time Insight in Biologic Manufacturing: Why PAT Matters for Commercial Scale-Up

David Alvaro, Ph.D.

Pharma's Almanac

Outsourcing Regs

Navigating Global Regulatory Expectations in Outsourced Manufacturing

David Alvaro, Ph.D.

Pharma's Almanac

DDCPs

Where Drugs Meet Devices: The Next Phase of Combination Product Innovation

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Sterile Supply Chain

The Fragile Backbone of Sterile Manufacturing: Container Closures, Filtration, and Supply Chain Resilience

David Alvaro, Ph.D.

Pharma's Almanac

FIll-Finish

Designing Flexible Fill-Finish Platforms for Small-Batch Precision Medicines

David Alvaro, Ph.D.

Pharma's Almanac

CCS

RABS or Isolators? Aligning Barrier Technology With Your Contamination Control Strategy

David Alvaro, Ph.D.

Pharma's Almanac

GCP

How Fully Owned, Locally Led Site Networks Deliver Quality, Speed, and Scalability in the Era of ICH E6(R3)

Łukasz Wiech, MD, MBA

Trialmed